
|Videos|October 20, 2022
Multiple Myeloma Clinical Trial Enrollment in the Black American Population
Author(s)Joseph Mikhael, MD, Craig Cole, MD
An expert discusses the stigmas behind clinical trials and the shockingly low rate of enrollment by Black Americans with multiple myeloma.
Episodes in this series

Related to this article

The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.

Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5



